Determination of hemolysis rate is a fundamental biocompatibility test used to evaluate the blood-damaging potential of medical devices, biomaterials, pharmaceuticals, and chemicals that come into contact with blood or mucosal surfaces. Performed in accordance with internationally recognized standards such as ISO 10993-4, ASTM F756, and GB/T 16886.4, this assay quantifies the release of hemoglobin from damaged erythrocytes using spectrophotometric techniques. This article explains the testing principles, sample types, methodologies, acceptance criteria, and practical applications of hemolysis rate determination in accredited third-party laboratories.
Technical Overview
Hemolysis refers to the rupture or damage of red blood cell (erythrocyte) membranes, resulting in the release of intracellular hemoglobin into the surrounding plasma or medium. The hemolysis rate is expressed as the percentage of erythrocytes lysed relative to complete (100%) lysis under defined experimental conditions. When the endpoint is defined at the midpoint of the dose–response curve, the assay is described as a half (50%) hemolysis determination, and the corresponding parameter is commonly reported as the HC50 value, that is, the concentration of a test substance or the dilution of a serum sample that produces 50% hemolysis of a standardized erythrocyte suspension.
For blood-contacting products, excessive hemolysis can cause anemia, hemoglobinuria, kidney injury, and platelet activation, making hemolysis testing a mandatory component of biological safety evaluation. The test is primarily governed by ISO 10993-4 (Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood), its Chinese counterpart GB/T 16886.4, and ASTM F756 (Standard Practice for Assessment of Hemolytic Properties of Materials). Quantification is typically performed by measuring the absorbance of released hemoglobin at approximately 540–545 nm using a UV-Visible spectrophotometer.
Under ASTM F756, materials are classified according to their hemolytic index:
- 0% to 2%: non-hemolytic
- Above 2% to 5%: slightly hemolytic
- Above 5%: hemolytic
A hemolysis rate below 5% is generally regarded as the acceptance threshold for most blood-contacting medical devices in regulatory submissions.
Testing Samples
Blood-Contacting Medical Devices
External communication devices and devices with circulating blood contact are the primary test subjects, including intravenous catheters, infusion sets, syringes, needles, blood collection tubes, blood bags, extracorporeal circuits, hemodialyzers, oxygenators, vascular stents, grafts, heart valves, and guide wires. Both the final finished product and its constituent materials can be evaluated.
Biomaterials and Surface Coatings
Polymeric materials, metals and alloys, ceramics, hydrogels, biodegradable scaffolds, antithrombotic or hydrophilic coatings, adhesives, and sterilization residues on device surfaces are routinely screened for hemolytic potential during material selection and process development.
Nanomaterials and Drug Products
Nanoparticles, liposomes, contrast agents, injectable formulations, excipients, and surfactants can be assessed using dedicated protocols, such as ASTM E2524, which addresses the hemolytic properties of nanoparticles. The HC50 value is widely used to rank the membrane-disrupting potency of detergents, venoms, and bioactive compounds.
Cosmetic, Oral Care, and Disinfection Products
Mouthwashes, toothpastes, dentifrices, antiseptic solutions, and disinfectants intended for contact with mucosal membranes or compromised skin may be evaluated for hemolytic activity as part of mucosal irritation and cytotoxicity assessment programs.
Clinical Serum Samples
In clinical immunology, the 50% hemolytic complement (CH50) assay is applied to serum or plasma to quantify the total functional activity of the classical complement pathway, supporting the diagnosis and monitoring of immune complex diseases, complement deficiencies, and autoimmune disorders.
Testing Items
Typical test items offered under hemolysis rate determination include:
- Direct contact hemolysis test: intact test samples are placed in direct contact with diluted anticoagulated blood.
- Indirect (extract) hemolysis test: test samples are first extracted in physiological saline or other vehicles, and the extract is mixed with diluted blood.
- Hemolysis ratio calculation: quantitative expression of the percentage of erythrocyte lysis induced by the test sample.
- HC50 determination: concentration–response analysis identifying the concentration of a test substance causing 50% hemolysis.
- CH50 assay: determination of the serum dilution producing 50% lysis of antibody-sensitized sheep erythrocytes, reported in complement activity units per milliliter.
- Plasma free hemoglobin quantification: measurement of cell-free hemoglobin as an indicator of in vitro or in vivo hemolytic activity.
- Hemolytic index classification: assignment of non-hemolytic, slightly hemolytic, or hemolytic categories per ASTM F756.
Testing Methods
Sample Preparation and Extraction
Samples are prepared under sterile conditions using a defined surface-area-to-extraction-medium ratio, commonly following the requirements of ISO 10993-12 for extraction conditions. Physiological saline (0.9% sodium chloride) is the standard extraction vehicle, and extraction is typically performed at 37 °C for a defined period. Liquid products may be tested directly or after dilution.
Blood Collection and Preparation
Fresh anticoagulated blood is obtained from healthy New Zealand white rabbits or human donors, using sodium citrate, heparin, or potassium oxalate as anticoagulant. Whole blood is diluted with physiological saline (for example, at a ratio of 8:10, blood to saline) immediately before use to ensure a linear photometric response and to avoid optical interference from undiluted hemoglobin.
Incubation and Controls
Aliquots of test sample, extract, negative control, and positive control are placed in triplicate tubes, and a defined volume of diluted blood is added to each tube. The tubes are incubated at 37 ± 0.5 °C for a standardized period, typically 2 to 3 hours with gentle inversion at intervals to maintain uniform contact. Physiological saline serves as the negative control (0% hemolysis), while distilled water or a detergent solution such as Triton X-100 or sodium dodecyl sulfate serves as the positive control (100% hemolysis).
Measurement and Calculation
After incubation, the tubes are centrifuged to pellet intact erythrocytes, and the supernatant absorbance is measured at 540–545 nm against a blank. The hemolysis rate is calculated as follows:
Hemolysis rate (%) = (A_sample − A_negative) / (A_positive − A_negative) × 100%, where A represents the absorbance values of the test sample, negative control, and positive control, respectively. For dose–response studies, the HC50 is derived by plotting hemolysis percentage against logarithmic concentration and interpolating the 50% endpoint, while CH50 assays apply the von Krogh transformation to the sigmoidal lysis curve to identify the dilution yielding 50% hemolysis of sensitized sheep red blood cells.
Result Evaluation
Results are interpreted against the applicable acceptance criteria: a hemolysis rate of 5% or below generally indicates acceptable blood compatibility, whereas values above 5% identify the sample as hemolytic and typically require design modification, material substitution, or risk-based justification. Test validity requires that the positive control achieves near-complete lysis and the negative control remains essentially free of hemolysis.
Applications
Hemolysis rate determination supports a wide range of regulatory, research, and quality control objectives:
- Biological safety evaluation and registration submissions for medical devices requiring blood contact claims, including national medical device market entry, FDA 510(k) submissions, and CE technical documentation.
- Material screening and selection during research and development, enabling comparison of polymers, coatings, surface treatments, and sterilization effects on blood compatibility.
- Batch-to-batch quality control for infusion, transfusion, and extracorporeal circulation consumables.
- Safety assessment of pharmaceutical excipients, injectables, nanomedicines, and surfactant-based formulations.
- Evaluation of oral care and disinfection products for mucosal compatibility.
- Clinical laboratory quantification of complement pathway activity through CH50 testing, supporting immunodeficiency and autoimmune diagnostics.
- Publication-grade data generation for academic research on erythrocyte membrane interactions and hemolytic toxicology.
FAQ
What does 50% hemolysis mean?
The 50% hemolysis endpoint defines the point at which half of the erythrocytes in a standardized suspension are lysed. In substance testing this is reported as the HC50, the concentration causing 50% lysis, and lower HC50 values indicate stronger hemolytic activity. In clinical complement testing, the CH50 represents the serum dilution producing 50% lysis of antibody-sensitized sheep erythrocytes and reflects total classical pathway complement activity.
Which standards govern hemolysis rate determination?
The principal standards are ISO 10993-4 and GB/T 16886.4 for blood interaction testing of medical devices, ASTM F756 for the hemolytic properties of materials, GB/T 14233.2 for infusion and transfusion equipment, and ASTM E2524 for nanoparticle hemolysis analysis. Testing should be performed by accredited third-party laboratories with documented competence in these methods.
What is the acceptance criterion for a blood-contacting device?
A hemolysis rate of 5% or less is the commonly applied acceptance limit, consistent with the ASTM F756 classification in which materials exceeding 5% are considered hemolytic. Specific product standards may define tighter limits depending on the intended use and duration of blood contact.
What is the difference between the direct and indirect hemolysis test?
The direct contact method places the physical test article in contact with diluted blood and evaluates surface-induced damage, making it suitable for solid devices. The indirect method tests an aqueous extract of the sample and captures leachable substances, making it appropriate for materials that release soluble compounds or cannot be cut into standardized geometries.
What blood source is used in the test?
Fresh anticoagulated rabbit blood is the conventional source for device testing because of its availability and established use in the reference methods, while human donor blood may be used where clinically representative conditions are required. Blood must be tested within a short window after collection, typically within a few hours, to preserve erythrocyte integrity.
What factors can cause false-positive or false-negative results?
Hemolyzed or aged blood, inadequate anticoagulation, particulate contamination, turbid or colored extracts that absorb near 540 nm, incomplete centrifugation, and improper incubation temperature can all distort absorbance readings. Blank correction, validated extraction conditions, and strictly timed sample-to-analysis intervals are essential for reliable results.
How long does a hemolysis test take?
The bench phase, including extraction, incubation, centrifugation, and photometric measurement, is typically completed within one day. Overall turnaround, including sample preparation, sterilization state verification where applicable, and reporting, generally ranges from five to ten working days depending on sample complexity and protocol requirements.
How is hemolysis rate different from a complete blood compatibility evaluation?
Hemolysis testing addresses only one category of blood interaction. A full evaluation per ISO 10993-4 may also require thrombosis, coagulation, platelet, leukocyte, and complement testing, with the test strategy determined by the nature, duration, and conditions of blood contact anticipated in clinical use.
